MediWound Ltd. (NASDAQ:MDWD - Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $19.40 and traded as high as $19.87. MediWound shares last traded at $19.54, with a volume of 54,974 shares traded.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the company. Alliance Global Partners began coverage on MediWound in a research report on Friday, May 2nd. They issued a "buy" rating and a $25.00 target price on the stock. HC Wainwright set a $31.00 target price on MediWound and gave the stock a "buy" rating in a report on Thursday, May 22nd. Oppenheimer assumed coverage on MediWound in a report on Monday, June 2nd. They set an "outperform" rating and a $34.00 target price on the stock. Craig Hallum assumed coverage on MediWound in a research report on Friday, February 28th. They issued a "buy" rating and a $39.00 price target for the company. Finally, Wall Street Zen upgraded MediWound to a "sell" rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Based on data from MarketBeat, MediWound currently has an average rating of "Moderate Buy" and a consensus price target of $31.80.
View Our Latest Research Report on MDWD
MediWound Stock Performance
The stock has a 50 day moving average price of $19.62 and a two-hundred day moving average price of $18.23. The company has a market capitalization of $208.20 million, a PE ratio of -9.22 and a beta of 0.38.
MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.58. MediWound had a negative return on equity of 74.12% and a negative net margin of 110.45%. The company had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. During the same period last year, the business earned ($1.05) EPS. Sell-side analysts predict that MediWound Ltd. will post -2.66 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in MediWound by 1,507.1% in the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,703 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,162 shares in the last quarter. Corebridge Financial Inc. boosted its stake in MediWound by 17.1% in the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 665 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 999 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in MediWound by 2,255.2% in the 1st quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company's stock valued at $98,000 after buying an additional 6,044 shares in the last quarter. 46.83% of the stock is owned by institutional investors.
About MediWound
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Read More
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
